Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.62 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771396 | 0.89 | PTGDR2 (0.50) | PTGDR2PTGDR | |
| SCHEMBL27735074 | 0.85 | PTGDR2 (0.45) | PTGDR2PTGDRAKR1B1TBXA2R | |
| SCHEMBL2770201 | 0.84 | PTGDR2 (0.75) | PTGDR2PTGDRAKR1B1 | |
| SCHEMBL2769552 | 0.81 | PTGDR2 (0.82) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL3577547 | 0.79 | PTGDR2 (0.65) | PTGDR2PTGDRAKR1B1 | |
| SCHEMBL3567663 | 0.79 | PTGDR2 (0.58) | PTGDR2PTGDRAKR1C3AKR1C2AKR1B1 | |
| SCHEMBL2769501 | 0.79 | PTGDR2 (0.64) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL27735075 | 0.78 | PTGDR2 (0.39) | PTGDR2 | |
| SCHEMBL3569319 | 0.77 | PTGDR2 (0.65) | PTGDR2PTGDRAKR1C3AKR1C2AKR1B1 | |
| SCHEMBL3570130 | 0.77 | PTGDR2 (0.56) | PTGDR2PTGDRAKR1C3AKR1C2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1910357-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163534-A1 | Indolizine Derivatives | HRH4, HRH2, NR1H2 | PTGDR2 363/4885PTGDR 270/4885AKR1C3 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.